Assenagon Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Assenagon Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-341,463	Closed	-$12.9M	–	1488
2021 Q1	$12.9M	Buy	341,463 +114,238	+50%	+$2.85M	0.05%	291
2020 Q4	$3.87M	Sell	227,225 -300,406	-57%	-$3.76M	0.02%	406
2020 Q3	$2.48M	Sell	527,631 -122,369	-19%	-$622K	0.01%	544
2020 Q2	$3.96M	Buy	650,000 +446,896	+220%	+$1.84M	0.03%	384
2020 Q1	$461K	Sell	203,104 -73,027	-26%	-$310K	﹤0.01%	656
2019 Q4	$1.27M	Sell	276,131 -211,726	-43%	-$839K	0.01%	530
2019 Q3	$1.89M	Buy	487,857 +91,578	+23%	+$502K	0.01%	413
2019 Q2	$2.39M	Buy	396,279 +241,579	+156%	+$2.31M	0.02%	474
2019 Q1	$2.07M	Buy	+154,700	New	+$1.76M	0.02%	508

Assenagon Asset Management's FPRX Position: Q2 2021 in Review

Assenagon Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 341,463 shares — an estimated $12.9M sold.

Assenagon Asset Management first reported a position in FPRX in Q1 2019 and held it in 9 quarters. The position peaked at $12.9M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Assenagon Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Assenagon Asset Management sold 341,463 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $12.9M.
Assenagon Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2019 and held it in 9 quarters.
Assenagon Asset Management's Five Prime Therapeutics, Inc. position peaked at $12.9M in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Assenagon Asset Management's 13F filing for Q2 2021, filed 15 Jul 2021.